Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383:2652–64.

Article  PubMed  CAS  Google Scholar 

Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.

Article  PubMed  Google Scholar 

Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–7.

Article  PubMed  Google Scholar 

Mayberry J. The history of 5-ASA compounds and their use in ulcerative colitis-trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis. 2013;22:375–7.

PubMed  Google Scholar 

Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141–50.

Article  PubMed  CAS  Google Scholar 

Ho GT, Cartwright JA, Thompson EJ, Bain CC, Rossi AG. Resolution of inflammation and gut repair in IBD: translational steps towards complete mucosal healing. Inflamm Bowel Dis. 2020;26:1131–43.

Article  PubMed  PubMed Central  Google Scholar 

Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779–89.

Article  PubMed  Google Scholar 

Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66–82.

Article  PubMed  PubMed Central  Google Scholar 

Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, et al. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol. 2022;22:44.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Panigrahy D, Gilligan MM, Serhan CN, Kashfi K. Resolution of inflammation: An organizing principle in biology and medicine. Pharmacol Ther. 2021;227:107879.

Article  PubMed  CAS  Google Scholar 

Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92–101.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Perretti M, Leroy X, Bland EJ, Montero-Melendez T. Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol Sci. 2015;36:737–55.

Article  PubMed  CAS  Google Scholar 

Perretti M, Godson C. Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology. Br J Pharmacol. 2020;177:4595–600.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Doyle R, Godson C, editors. Chapter 5 - Endogenous antiinflammatory and proresolving lipid mediators in renal disease. United States: Academic Press; 2022. p 55–67.

Zhang H, Lu Y, Sun G, Teng F, Luo N, Jiang J, et al. The common promoter polymorphism rs11666254 downregulates FPR2/ALX expression and increases risk of sepsis in patients with severe trauma. Crit Care. 2017;21:171.

Article  PubMed  PubMed Central  Google Scholar 

Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2:521–30.

Article  PubMed  Google Scholar 

Brennan EP, Cacace A, Godson C. Specialized pro-resolving mediators in renal fibrosis. Mol Aspects Med. 2017;58:102–13.

Article  PubMed  CAS  Google Scholar 

Crocetti L, Vergelli C, Guerrini G, Giovannoni MP, Kirpotina LN, Khlebnikov AI, et al. Pyridinone derivatives as interesting formyl peptide receptor (FPR) agonists for the treatment of rheumatoid arthritis. Molecules. 2021;26:6583.

Qin CX, May LT, Li R, Cao N, Rosli S, Deo M, et al. Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nat Commun. 2017;8:14232.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Possebon L, Costa SS, Souza HR, Azevedo LR, Sant’Ana M, Iyomasa-Pilon MM, et al. Mimetic peptide AC2-26 of annexin A1 as a potential therapeutic agent to treat COPD. Int Immunopharmacol. 2018;63:270–81.

Article  PubMed  CAS  Google Scholar 

Stama ML, Ślusarczyk J, Lacivita E, Kirpotina LN, Schepetkin IA, Chamera K, et al. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. Eur J Med Chem. 2017;141:703–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim SD, Kwon S, Lee SK, Kook M, Lee HY, Song KD, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis. Exp Mol Med. 2013;45:e40.

Article  PubMed  PubMed Central  Google Scholar 

Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. Eur J Med Chem. 2021;213:113167.

Article  PubMed  CAS  Google Scholar 

Yang WS, Wang JL, Wu W, Wang GF, Yan J, Liu Q, et al. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease. Acta Pharmacol Sin. 2023;44:19–31.

Article  PubMed  CAS  Google Scholar 

Duan J, Shen DD, Zhou XE, Bi P, Liu QF, Tan YX, et al. Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. Nat Commun. 2020;11:4121.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liang YL, Zhao P, Draper-Joyce C, Baltos JA, Glukhova A, Truong TT, et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination. ACS Pharmacol Transl Sci. 2018;1:12–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhuang Y, Liu H, Edward Zhou X, Kumar Verma R, de Waal PW, Jang W, et al. Structure of formylpeptide receptor 2-G(i) complex reveals insights into ligand recognition and signaling. Nat Commun. 2020;11:885.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhu Y, Lin X, Zong X, Han S, Wang M, Su Y, et al. Structural basis of FPR2 in recognition of Aβ42 and neuroprotection by humanin. Nat Commun. 2022;13:1775.

Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47:1739–49.

Article  PubMed  CAS  Google Scholar 

Nanamori M, Cheng X, Mei J, Sang H, Xuan Y, Zhou C, et al. A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004;66:1213–22.

Article  PubMed  CAS  Google Scholar 

Zhou C, Zhang S, Nanamori M, Zhang Y, Liu Q, Li N, et al. Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007;72:976–83.

Article  PubMed  CAS  Google Scholar 

Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295–309.

Article  PubMed  CAS  Google Scholar 

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22:1402–10.

Article  PubMed  PubMed Central  CAS